NCT02340910

Brief Summary

This study will enroll people with SCI who have spasticity and some ability to walk. The goal is to understand if standing on a platform and receiving WBV results in decreased spasticity and improved walking ability. Published article is available (PMID: 29959653)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
46

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2015

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 9, 2015

Completed
10 days until next milestone

First Posted

Study publicly available on registry

January 19, 2015

Completed
14 days until next milestone

Study Start

First participant enrolled

February 2, 2015

Completed
5.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 6, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 6, 2020

Completed
Last Updated

March 9, 2021

Status Verified

March 1, 2021

Enrollment Period

5.1 years

First QC Date

January 9, 2015

Last Update Submit

March 8, 2021

Conditions

Keywords

spasticitywhole body vibrationwalking

Outcome Measures

Primary Outcomes (1)

  • Spasticity Assessments

    Pendulum test, Spinal Cord Injury Spasticity Evaluation Tool (SCI-SET) Questionnaire, Electrophysiological testing (Soleus H-reflex)

    Estimated 1 hour

Secondary Outcomes (5)

  • Walking ability

    Estimated 30 minutes

  • Strength

    Estimated 20 minutes

  • Pain perception

    Estimated 20 minutes

  • Upper Extremity Tests

    Estimated 5 minutes

  • Ankle Clonus Test/Foot

    Estimated 15 minutes

Study Arms (2)

Short duration

EXPERIMENTAL

Short Duration WBV consists of 8 45-sec bouts of 50Hz WBV followed by a 1-minute seated rest

Procedure: Short Duration

Long duration

EXPERIMENTAL

Long Duration WBV consists of 16 bouts 45-sec of 50Hz WBV followed by a 1-minute seated rest

Procedure: Long Duration

Interventions

During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 6 minutes of WBV at a frequency of 50 Hz.

Short duration
Long DurationPROCEDURE

During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 12 minutes of WBV at a frequency of 50 Hz. Interventions will occur for a total of 20 sessions over 4 consecutive weeks .

Long duration

Eligibility Criteria

Age16 Years - 72 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shepherd Center, Inc.

Atlanta, Georgia, 30309, United States

Location

Related Publications (1)

  • Estes S, Iddings JA, Ray S, Kirk-Sanchez NJ, Field-Fote EC. Comparison of Single-Session Dose Response Effects of Whole Body Vibration on Spasticity and Walking Speed in Persons with Spinal Cord Injury. Neurotherapeutics. 2018 Jul;15(3):684-696. doi: 10.1007/s13311-018-0644-1.

    PMID: 29959653BACKGROUND

Related Links

MeSH Terms

Conditions

Spinal Cord InjuriesMuscle Spasticity

Condition Hierarchy (Ancestors)

Spinal Cord DiseasesCentral Nervous System DiseasesNervous System DiseasesTrauma, Nervous SystemWounds and InjuriesMuscular DiseasesMusculoskeletal DiseasesMuscle HypertoniaNeuromuscular ManifestationsNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Masked allocation and intervention
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 9, 2015

First Posted

January 19, 2015

Study Start

February 2, 2015

Primary Completion

March 6, 2020

Study Completion

March 6, 2020

Last Updated

March 9, 2021

Record last verified: 2021-03

Locations